Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 13/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31352747 | 0.90 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL8501994 | 0.87 | KDM4E (0.77) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL14258169 | 0.87 | SMN1; SMN2 (0.77) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL28105912 | 0.86 | SMN1; SMN2 (0.75) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL1571438 | 0.86 | SMN1; SMN2 (0.75) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL14146492 | 0.86 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL558219 | 0.84 | KDM4E (0.70) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL6030063 | 0.83 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL28344313 | 0.82 | SMN1; SMN2 (0.67) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL27352432 | 0.81 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2KDM4EPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107245072-A | A kind of preparation method of the triazole compound of Tarceva 1,2,3 | 河南师范大学 | 2017-10-13 | — | — | CN | claimed |
| CN-106946857-A | 3-triazole compounds of Tarceva 1,2,3 with antitumor activity and its preparation method and application | 河南师范大学 | 2017-07-14 | — | — | CN | claimed |
| CN-106632271-A | Erlotinib derivative with antitumor activity, and preparation method and application thereof | 河南师范大学 | 2017-05-10 | — | — | CN | claimed |
| CN-103509005-A | Quinazoline compound as well as preparation method and application thereof | SUZHOU HAITE BIAO BIOLOG TECHNOLOGY CO LTD | 2014-01-15 | — | — | CN | claimed |
| CN-101353328-B | Preparation of 2-chlorin-4-amido-6,7-dimethoxy quinazoline | CHONGQING WORLD HAORUI PHARM CHEM CO LTD | 2010-12-15 | — | — | CN | claimed |
| CN-101353328-A | Preparation of 2-chlorin-4-amido-6,7-dimethoxy quinazoline | CHONGQING WORLD HAORUI PHARM C (CN) | 2009-01-28 | — | — | CN | claimed |
| WO-2007144699-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (US) | 2007-12-21 | — | — | WO | claimed |
| JP-62056488-A | — | — | None | — | — | JP | disclosed |
| JP-8134066-A | — | — | None | — | — | JP | disclosed |
| EP-4236928-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1Cbio, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| CN-1061411-A | Be used to strengthen the active quinazoline derivant of antineoplastic agent | PFIZER (US) | 1992-05-27 | — | — | CN | disclosed |
| EP-0188094-B1 | QUINAZOLINE DERIVATIVES AND ANTIHYPERTENSIVE PREPARATIONS CONTAINING SAME AS EFFECTIVE COMPONENTS | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4959368-A | PYRIMIDINE DERIVATIVES | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) | 1990-09-25 | — | — | US | disclosed |
| US-4734418-A | Quinazoline compounds and antihypertensives | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0257102-A1 | AGENTS FOR TREATING NEUROPHATHY | Mitsui Chemicals, Inc. (JP) | 1988-03-02 | — | — | EP | disclosed |
| JP-S6256488-A | QUINAZOLINE DERIVATIVE AND PHARMACEUTICAL USE | MITSUI PETROCHEM IND LTD | 1987-03-12 | — | — | JP | disclosed |
| EP-0188094-A2 | Quinazoline derivatives and antihypertensive preparations containing same as effective components | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | ALDH1A1 3311/4885SMN1; SMN2 3567/4885KDM4E 4559/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ALDH1A1 1769/4885SMN1; SMN2 3306/4885KDM4E 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.